The American Journal of Managed Care5d
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
The American Journal of Managed Care9d
CROI to Present New Insights on Long COVID Risk, HIV Cure
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
aidsmap12d
aidsmap returns with reporting from the Conference on Retroviruses and Opportunistic Infections (CROI)
News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...
Healio2d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Medpage Today on MSN17h
Study Suggests Higher Odds of Congenital Syphilis With 9-Day Treatment Interval
Johnson's group demonstrated in a 2023 study that congenital syphilis is not more likely with a prenatal dose schedule using ...
El Mundo on MSN4d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
Bay Area Reporter4d
At CROI conference, HIV activists sound alarm on Trump policies
AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
Healio2d
Long-acting treatment benefits postpartum women with HIV and their babies
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...